Hanmi Science is a business-oriented holding company that generates revenue from equity interests, patent and trademark royalties, and direct healthcare operations. Its business segments include a holding division, a healthcare division, and a pharmaceutical wholesale division. The healthcare division comprises medical devices, consumer health products such as soy milk and functional foods, beauty care, and IT solutions for the pharmaceutical industry. The wholesale division operates the HMP Mall B2B e-commerce platform and a nationwide sales network to distribute pharmaceuticals, quasi-drugs, health functional foods, and automatic dispensing machines to pharmacies and hospitals. Key subsidiaries include Hanmi Pharm, which develops and manufactures drugs such as Amodactan, Rosujet, and Esomezol; J.V.M, which provides pharmacy and hospital automation systems; and Online Pharm, which handles pharmaceutical distribution. The group also includes Hanmi Precision Chemical for active pharmaceutical ingredients, Hanmi Europe Ltd. and Japan Hanmi Pharm for international expansion, and Evidnet for database and online information services. Hanmi Science serves domestic and international markets, with subsidiaries operating in Japan, Europe, and China.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage hanmiscience.co.kr
Sector Healthcare IR page —
Tags
holding company, innovative drugs, complex generics, pharmaceutical distribution, pharmacy automation, medical devices, consumer health, functional foods, beauty care, pharmaceutical it, active pharmaceutical ingredients, Hanmi Pharm, J.V.M, Online Pharm, Hanmi Precision Chemical, Hanmi Europe Ltd., Japan Hanmi Pharm, Beijing Hanmi IT Co. Ltd., Evidnet, Amodactan, Rosujet, Esomezol, Palpal, Rovelito, HMP Mall, Hanmi Healthcare
Press page —

Metrics

Valuation  
Market cap ₩ 3.014T
Market cap (USD) $ 2.219B
P/E 19.79
PEG 1.01
P/BV 2.84
P/S 2.14
P/OCF 64.29
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 13.1%
ROI 12.3%
ROIC 12.8%
Profit margin 8.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 19.6%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.357T 1.283T 1.248T 1.046T 950.165B 857.383B 816.619B 707.995B 652.324B 665.285B 776.629B 532.886B 220.396B
Net profit 118.37B 59.422B 115.122B 69.21B 42.942B 22.597B 30.742B 18.02B 30.069B 7.94B 177.45B 21.862B 9.598B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 38K 29.516K — — — — — — — — — — —
Price performance 12m 0.29 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 127B 108B 101B 91.1B 87.9B 94.2B 99.8B 109B 103B 105B
↳ YoY growth -47.0% -15.5% -5.7% -10.2% -3.5% +7.2% +5.9% +8.8% -5.3% +2.5%
↳ 5y CAGR +9.2% -6.2% -18.2% -5.8% -1.5% +1.4% +2.5% +3.7%
Borrowings, current (KRW) 25B 25B 20B 44B 45B 55B 194B 202B 215B 213B
Borrowings, non-current (KRW) — — 0.00 0.00 5B 0.00 5.82B 10.2B 350M 0.00
Cash and deposits (KRW) 103B 38.4B 26.9B 16.7B 14.8B 16.6B 21.4B 27.6B 85.2B 127B
Intangible assets (KRW) 8.47B 12.5B 11.2B 10.4B 8.81B 7.58B 19.1B 67.1B 54.5B 15.7B
Right-of-use assets (KRW) — 0.00 0.00 1.4B 1.39B 1.45B 2.44B 1.77B 1.81B 1.19B
Net debt (borrowings + leases - cash) (KRW) -77.5B -13.4B -6.86B 27.3B 35.2B 38.4B 178B 185B 130B 85.9B
Cash flow detail
Operating cash flow (KRW) 76.5B -33.7B 2.7B 13B 13.8B 13.7B 9.45B 35.2B 83B 47.7B
Change in receivables (cash effect) (KRW) 116B 19.5B 33.7M 9.43B 3.6B -5.41B 3.74B -8.78B 5.44B -3.12B
Change in inventories (cash effect) (KRW) -3.58B -14.3B 5.55B 2.73B -8.52B 2.73B 6.24B 9.71B -4.05B -13.9B
Change in payables (cash effect) (KRW) 2.5B -38.2B -5.46B -14.3M -331M -18.7B -40.2B -19.2B 68.8B -1.56B
Dividends paid (cash effect) (KRW) -27.6B 0.00 -12.2B -12.4B -12.7B -12.9B -13.2B -13.3B -20.3B -13.5B
Share buybacks (cash effect) (KRW) -1.77B -835M -998M -647M -348M -1.01B -623M -7.83B -1.93B 0.00
Interest paid (cash effect) (KRW) -975M -751M -624M -1.22B -1.13B -1B -2.6B -9.53B -9.28B -7.73B
Income taxes paid (cash effect) (KRW) -44.9B -22.7B -4.39B -2.96B -3.48B -5.66B -5.35B -4.25B -9.28B -10.6B
Share-based compensation (KRW) 13.5B 1.27B 0.00 0.00 — — 0.00 0.00 553M 211M
Operating cash flow before change in receivables (KRW) -39.1B -53.2B 2.67B 3.59B 10.2B 19.1B 5.71B 43.9B 77.5B 50.8B
Income detail
Total comprehensive income (KRW) 910M 27.7B 12.1B 5.7B — 45.5B 67.2B 83.9B 72.9B 132B
Comprehensive income to owners (KRW) 979M 27B 12.1B 5.69B — 45.5B 67.4B 83.9B 75.7B 133B
Provision for credit losses (KRW) 0.00 531M 0.00 0.00 35.4M 52.9M 0.00 341M 0.00 212M
Credit cost ratio (credit losses / average receivables) (%) 0.0% 0.5% 0.0% 0.0% 0.0% 0.1% 0.0% 0.3% 0.0% 0.2%
Reported Apr 2, 2018 Mar 30, 2020 Mar 18, 2021 Mar 18, 2021 Mar 18, 2021 Mar 28, 2024 Mar 18, 2025 Mar 18, 2025 Mar 18, 2025 Mar 20, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

주식등의대량보유상황보고서(일반) Bull 0 Bear 0 Routine

Prompts

Hanmi Science (ticker 008930), listed in South Korea.

ETFs Holding Hanmi Science

ETF Weight in ETF Shares Market value As of
AVEE 0.10% 3,500 $ 137.478K Nov 16, 2026
DFEV 0.02% 11,202 $ 461.4K Nov 12, 2026
DFSE 0.02% 2,133 $ 87.856K Nov 12, 2026
DEXC 0.01% 932 $ 38.388K Nov 12, 2026
AVXC 0.01% 807 $ 31.699K Nov 16, 2026
DFEM 0.01% 17,264 $ 711.088K Nov 12, 2026
DFAE 0.00% 9,329 $ 384.253K Nov 12, 2026
DFAX 0.00% 11,875 $ 489.12K Nov 12, 2026
AVEM 0.00% 10,244 $ 402.379K Nov 16, 2026